<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967340</url>
  </required_header>
  <id_info>
    <org_study_id>RC18_0351</org_study_id>
    <nct_id>NCT03967340</nct_id>
  </id_info>
  <brief_title>PREdiction of Chronic LUng Allograft Dysfunction</brief_title>
  <acronym>PRELUD</acronym>
  <official_title>PREdiction of Chronic LUng Allograft Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic lung allograft dysfunction (CLAD) is the leading cause of long-term mortality after&#xD;
      lung transplantation. Several risk factors for CLAD have been identified, but the exact&#xD;
      pathophysiology and triggering molecular factors remain largely unknown. Moreover, in&#xD;
      clinical practice, no integration of the different risk factors is achieved. CLAD is&#xD;
      therefore diagnosed most often late with the persistent decline in respiratory function,&#xD;
      revealing a profound and irreversible alteration of the pulmonary graft. Several blood&#xD;
      biomarkers that can predict the occurrence of CLAD more than 6 months before clinical&#xD;
      diagnosis have been identified and validated. From these preliminary results, a composite&#xD;
      score is being developed from independent samples from the COLT (COhort in Lung&#xD;
      Transplantation) cohort. The main objective of this project is to validate this robust and&#xD;
      predictive composite score (biological and clinical) of CLAD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMP-9 levels in plasma, gene expression and lymphocyte levels in blood associated with Chronic Lung Allograft Dysfunction (CLAD)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of the 3 genes BLK, POU2AF1 and TCL1A in whole blood associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMP-9 levels over time associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transitional B lymphocytes rate over time associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T lymphocytes levels over time associated with CLAD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">240</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Lung transplant</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and serum will be collected and retained in a biorepository&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly enrolled on the waiting list in transplant centres will be included in the&#xD;
        PRELUD study.&#xD;
&#xD;
        Based on the number of annual transplants in France (300/year), we plan to include 240&#xD;
        patients at the time of their registration on the transplant waiting list. Of these 240&#xD;
        patients, we estimate that 190 patients will be transplanted.&#xD;
&#xD;
        It will be possible to include patients in emergencies. In this case, the consent of a&#xD;
        trusted person or relative will be obtained and then the patient will give his or her&#xD;
        consent as soon as his or her condition permits.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients to receive lung transplants awaiting registration on the transplant waiting&#xD;
             list&#xD;
&#xD;
          -  Patients affiliated to a social security system&#xD;
&#xD;
          -  Patients who have given their informed consent&#xD;
&#xD;
          -  Patients weighing more than 26 kg&#xD;
&#xD;
          -  Patients over 16 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients unable to follow the protocol&#xD;
&#xD;
          -  Patients with concomitant inflammatory diseases, regardless of acute, chronic or&#xD;
             infectious rejection.&#xD;
&#xD;
          -  Patients with a history of cancer in remission for less than 5 years, with the&#xD;
             exception of localized skin cancers, excluding melanoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrien TISSOT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lung allograft dysfunction</keyword>
  <keyword>lung transplantation</keyword>
  <keyword>biomarkers</keyword>
  <keyword>personalized medecine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

